Minimal Differences Between Anti-VEGF Drugs on IOP Over Time

Source: Medscape

Friday, June 02, 2017 | Medical Studies

Patients on anti-VEGF therapy may have a small decrease in intraocular pressure (IOP) over time, but with minimal differences between aflibercept, ranibizumab, and bevacizumab, a new large study suggests. "The differences in IOP between aflibercept, ranibizumab, and bevacizumab were statistically significant; however, overall they were small, suggesting no clinically relevant difference between these drugs and changes in IOP over time,” the authors said in their abstract.

Open in New Window


You must be logged in to leave a comment.